Citing our products is easier than ever: every item on our website has an RRID. Cite easily, promote reproducibility: https://lnkd.in/eR83zwEZ
BioSpherix, LLC
生物技术研究
Parish,NY 1,814 位关注者
Cytocentric? technology for optimal cell processioning and manufacturing
关于我们
BioSpherix, LLC. is dedicated to the development, manufacture, and sale of highly advanced laboratory equipment for the purpose of controlling and maintaining in-vitro (cell) and in-vivo (animal) environments. Check out our Cytocentric blog at https://www.biospherix.com/cytocentric Follow us on Twitter at https://twitter.com/BioSpherix or on Facebook at https://facebook.com/BiospherixLtd
- 网站
-
https://www.BioSpherix.com
BioSpherix, LLC的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Parish,NY
- 类型
- 私人持股
- 创立
- 2001
- 领域
- Lab Equipment for Cell Research & Animal Modeling, specializing in hypoxia control.
地点
-
主要
25 Union Street
US,NY,Parish,13131
BioSpherix, LLC员工
-
Kayla Nolan
Classification Specialist at BioSpherix Medical
-
Timothy Lee
Experienced Business Development and Sales Professional in Stem Cell Research, Regen Med and Cellular Therapy Devices
-
Syed Ahmed Mustafa
President/CEO | Private Equity | Sales Leadership and Training | Marketing | Manufacturing | International Sales | Life Science | Business…
-
Susan Linerode, M.Ed
Professional Sales Rep currently facilitating increased reproducibility and translatability in cell culturing through technology that allows…
动态
-
#sitc2024 Have you stopped by booth #1019 yet? Timothy Lee, Syed Ahmed Mustafa, and Alicia Henn are having a great time at the Society for Immunotherapy of Cancer (SITC) discussing cutting-edge research and cell processing techniques with fellow science enthusiasts! Pay them a visit to learn how our Xvivo System can benefit your cancer cell and immunotherapy research! Prepare to be wowed!
-
All set up at the Society for Immunotherapy of Cancer (SITC) and ready to discuss Cytocentric principles at booth #1019! Feel free to stop by - we'd love to chat with you! In vivo, in vitro, GMP, we do it all! How can a BioSpherix system streamline and improve your cell research? #SITC2024 #SITC
-
BioSpherix President Syed Ahmed Mustafa had another great series of meetings at the Wake Forest Institute for Regenerative Medicine. As he often does, he stopped by the WFIRM Test Bed, a unique facility available to researchers and product developers to experience a multitude of different types of equipment, including the BioSpherix Xvivo System?.? ? Ahmed and WFIRMs Karen Barnes spent some time touring the facility and discussing ways to introduce more people within the Piedmont Triad region to the Test Bed. ? Stay tuned for more exciting news about BioSpherix and our ongoing commitment to support the advancement of regenerative medicine in the NSF Piedmont Triad RegenMed Engine.
-
Did you miss our November newsletter? Check it out! If you'd like to subscribe for our newsletters and other updates, visit our News and Events page and enter your information in our signup prompt. https://lnkd.in/g5wWcK8C
-
BioSpherix President and CEO, Syed Ahmed Mustafa, will join a panel discussion on integrating sustainability into product development on Thursday, November 14th. Don’t miss this insightful session! Details for registration below.
Join us in Rochester for Together '24! We'll hear perspectives on the topic of Sustainability from Syed Ahmed Mustafa, BioSpherix, LLC; Matthew Hall, Corning Incorporated; and Colin Wright, Thermo Fisher Scientific. Discussion will be moderated by Nipa Mody, QuidelOrtho. Register here: https://lnkd.in/eU7_BTqM #makinghealthbettertogether #sustainability #lifesciences
-
Check out this recent article from the Journal of Biomaterials and Nanotechnology which talks about the GMP production of MSC's as an alternative for mitochondrial organelle transplantation (MOT) using a BioSpherix Xvivo System X2: "In order to overcome the disadvantages of routine MOT by using fresh cells for mitochondrial donors, we are exploring an enhanced methodology for MOT clinical trials. Current Good Manufacturing Practice (cGMP)—fibroblasts or MSCs will be expanded and banked in a central cGMP compliant cell factory. The frozen cells will be cryogenically shipped to multiple clinical sites where have installed BioSpherix Xvivo System X2. The system is a portable ISO Class 5 closed aseptic isolator, and designed for producing and processing cells in compliance with regulatory GMPs?[22]. Mitochondria will be isolated from the cryopreserved cells in the Xvivo System X2. The isolated mitochondria will be injected to patients after isolation as soon as possible." Read the full article here: https://lnkd.in/gHg2YXhs
Cryopreserved Fibroblast and Mesenchymal Stem Cells (MSCs) Being Alternative Mitochondrial Donors for Mitochondrial Organelle Transplantation (MOT)
scirp.org